000			02185 a2200613 4500
005			20250517192820.0
264		0	_c20180917
008			201809s 0 0 eng d
022			_a1349-7235
024	7		_a10.2169/internalmedicine.9479-17 _2doi
040			_aNLM _beng _cNLM
100	1		_aHirayama, Takeshi
245	0	0	_aDifferences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment. _h[electronic resource]
260			_bInternal medicine (Tokyo, Japan) _cMay 2018
300			_a1219-1227 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAged
650	0	4	_aAnilides _xtherapeutic use
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aCarbamates _xtherapeutic use
650	0	4	_aCase-Control Studies
650	0	4	_aCyclopropanes
650	0	4	_aCytochrome P-450 CYP3A _xmetabolism
650	0	4	_aDrug Therapy, Combination
650	0	4	_aFemale
650	0	4	_aGenotype
650	0	4	_aHepatitis C _xdrug therapy
650	0	4	_aHepatitis C, Chronic _xdrug therapy
650	0	4	_aHumans
650	0	4	_aHydroxycholesterols _xblood
650	0	4	_aImidazoles _xtherapeutic use
650	0	4	_aInterferons _xadministration & dosage
650	0	4	_aIsoquinolines _xtherapeutic use
650	0	4	_aLactams, Macrocyclic
650	0	4	_aMacrocyclic Compounds _xtherapeutic use
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aProline _xanalogs & derivatives
650	0	4	_aPyrrolidines
650	0	4	_aRitonavir _xtherapeutic use
650	0	4	_aSex Factors
650	0	4	_aSulfonamides _xtherapeutic use
650	0	4	_aTreatment Failure
650	0	4	_aValine _xanalogs & derivatives
700	1		_aIkegami, Tadashi
700	1		_aHonda, Akira
700	1		_aMiyazaki, Teruo
700	1		_aYara, Sho-Ichiro
700	1		_aKohjima, Motoyuki
700	1		_aNakamuta, Makoto
700	1		_aMatsuzaki, Yasushi
773	0		_tInternal medicine (Tokyo, Japan) _gvol. 57 _gno. 9 _gp. 1219-1227
856	4	0	_uhttps://doi.org/10.2169/internalmedicine.9479-17 _zAvailable from publisher's website
999			_c27926794 _d27926794